Accuracy of [68Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathology.

[1]  V. Drendel,et al.  Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  A. Scherz,et al.  Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy , 2017, Clinical Cancer Research.

[3]  E. Krenning,et al.  Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results , 2017, The Journal of Nuclear Medicine.

[4]  V. Drendel,et al.  Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET , 2016, Theranostics.

[5]  C. Zamboglou,et al.  68Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison , 2016, Theranostics.

[6]  Andrei Iagaru,et al.  Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[7]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[8]  I. Burger,et al.  Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[9]  U. Haberkorn,et al.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer , 2014, Pharmaceuticals.

[10]  J. Reubi,et al.  Early over‐expression of GRP receptors in prostatic carcinogenesis , 2014, The Prostate.

[11]  I. Jambor,et al.  In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.

[12]  W. Weber,et al.  Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin , 2013, The Journal of Nuclear Medicine.

[13]  S. Kneifel,et al.  Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides , 2009, Clinical Cancer Research.

[14]  Sven Perner,et al.  Imaging prostate cancer with 11C-choline PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[16]  R. Jensen,et al.  Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP). , 2005, Biochemical pharmacology.

[17]  J. Reubi,et al.  Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] Bombesin(6–14) , 2002 .

[18]  G. Slegers,et al.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.

[19]  J C Reubi,et al.  Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. , 1999, Cancer research.

[20]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, JAMA.

[21]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[23]  F. Forrer,et al.  Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .

[25]  R. Coleman,et al.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. , 2001, Cancer research.